Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models

[1]  N. Maragakis,et al.  Neural and glial progenitor transplantation as a neuroprotective strategy for Amyotrophic Lateral Sclerosis (ALS) , 2015, Brain Research.

[2]  V. Wheelock,et al.  Developing stem cell therapies for juvenile and adult-onset Huntington’s disease , 2015, Regenerative medicine.

[3]  Elizabeth G Loboa,et al.  Our Fat Future: Translating Adipose Stem Cell Therapy , 2015, Stem cells translational medicine.

[4]  Hafsa Munir,et al.  Mesenchymal Stem Cell Therapy for Autoimmune Disease: Risks and Rewards. , 2015, Stem cells and development.

[5]  C. Lombard,et al.  Mesenchymal stem cell treatment for hemophilia: a review of current knowledge , 2015, Journal of thrombosis and haemostasis : JTH.

[6]  J. Nolta,et al.  Hypoxic Preconditioning of Mesenchymal Stromal Cells Induces Metabolic Changes, Enhances Survival, and Promotes Cell Retention In Vivo , 2015, Stem cells.

[7]  M. Hoogduijn,et al.  Efficacy of immunotherapy with mesenchymal stem cells in man: a systematic review , 2015, Expert review of clinical immunology.

[8]  M. Hayden,et al.  Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease , 2015, Neurobiology of Disease.

[9]  S. E. Berry.  Concise Review: Mesoangioblast and Mesenchymal Stem Cell Therapy for Muscular Dystrophy: Progress, Challenges, and Future Directions , 2015, Stem cells translational medicine.

[10]  C. Svendsen,et al.  The past, present and future of stem cell clinical trials for ALS , 2014, Experimental Neurology.

[11]  K. Uth,et al.  Stem cell application for osteoarthritis in the knee joint: A minireview. , 2014, World journal of stem cells.

[12]  R. D. dos Santos,et al.  Safety and neurological assessments after autologous transplantation of bone marrow mesenchymal stem cells in subjects with chronic spinal cord injury , 2014, Stem Cell Research & Therapy.

[13]  M. Gutiérrez-Fernández,et al.  Reparative therapy for acute ischemic stroke with allogeneic mesenchymal stem cells from adipose tissue: a safety assessment: a phase II randomized, double-blind, placebo-controlled, single-center, pilot clinical trial. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[14]  K. Biglan,et al.  Current therapeutic options for Huntington's disease: Good clinical practice versus evidence‐based approaches? , 2014, Movement disorders : official journal of the Movement Disorder Society.

[15]  D. Chuang,et al.  Preclinical and Clinical Investigations of Mood Stabilizers for Huntington's Disease: What Have We Learned? , 2014, International journal of biological sciences.

[16]  P. Rameshwar,et al.  Stem cell delivery of therapies for brain disorders , 2014, Clinical and Translational Medicine.

[17]  M. Rudnicki,et al.  Efficacy and safety of mesenchymal stromal cells in preclinical models of acute lung injury: a systematic review protocol , 2014, Systematic Reviews.

[18]  E. Feldman,et al.  Concise Review: Stem Cell Therapies for Amyotrophic Lateral Sclerosis: Recent Advances and Prospects for the Future , 2014, Stem cells.

[19]  Allison Hubel,et al.  Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices , 2014, Transfusion.

[20]  H. Cheung,et al.  Progress of mesenchymal stem cell therapy for neural and retinal diseases. , 2014, World journal of stem cells.

[21]  N. Bresolin,et al.  Stem cell transplantation for amyotrophic lateral sclerosis: therapeutic potential and perspectives on clinical translation , 2014, Cellular and Molecular Life Sciences.

[22]  J. Rossignol,et al.  Transplants of Adult Mesenchymal and Neural Stem Cells Provide Neuroprotection and Behavioral Sparing in a Transgenic Rat Model of Huntington's Disease , 2014, Stem cells.

[23]  J. Bergado,et al.  BDNF in quinolinic acid lesioned rats after bone marrow cells transplant , 2014, Neuroscience Letters.

[24]  R. Maziarz,et al.  Adult adherent stromal cells in the management of graft-versus-host disease , 2014, Expert opinion on biological therapy.

[25]  W. Crum,et al.  Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the R6/1 Mouse Model of Huntington’s Disease , 2013, PloS one.

[26]  A. Caplan,et al.  Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine , 2013, Experimental & Molecular Medicine.

[27]  A. Benraiss,et al.  Sustained mobilization of endogenous neural progenitors delays disease progression in a transgenic model of Huntington's disease. , 2013, Cell stem cell.

[28]  G. Bernardi,et al.  Systemic Delivery of Recombinant Brain Derived Neurotrophic Factor (BDNF) in the R6/2 Mouse Model of Huntington’s Disease , 2013, PloS one.

[29]  P. Popoli,et al.  BDNF prevents NMDA‐induced toxicity in models of Huntington's disease: the effects are genotype specific and adenosine A2A receptor is involved , 2013, Journal of neurochemistry.

[30]  J. Cloutier,et al.  Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease , 2013, Genes, brain, and behavior.

[31]  Zhixiang Wang,et al.  Noggin suppression decreases BMP‐2‐induced osteogenesis of human bone marrow‐derived mesenchymal stem cells In Vitro , 2012, Journal of cellular biochemistry.

[32]  Aaron R Cooper,et al.  Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. , 2012, Blood.

[33]  A. Reiner,et al.  BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice , 2012, Brain Research.

[34]  J. Nolta,et al.  Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin , 2012, Molecular and Cellular Neuroscience.

[35]  Daniel T. Montoro,et al.  Enhancement of Human Adipose-Derived Stromal Cell Angiogenesis through Knockdown of a BMP-2 Inhibitor , 2012, Plastic and reconstructive surgery.

[36]  V. Wheelock,et al.  Genetically Engineered Mesenchymal Stem Cells as a Proposed Therapeutic for Huntington’s Disease , 2011, Molecular Neurobiology.

[37]  S. Dunnett,et al.  Clinical translation of cell transplantation in the brain , 2011, Current opinion in organ transplantation.

[38]  Eduardo D. Martín,et al.  Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction , 2011, Molecular Neurodegeneration.

[39]  A. Benraiss,et al.  Cellular Therapy and Induced Neuronal Replacement for Huntington’s Disease , 2011, Neurotherapeutics.

[40]  A. Benraiss,et al.  Sustained induction of neuronal addition to the adult rat neostriatum by AAV4-delivered noggin and BDNF , 2011, Gene Therapy.

[41]  L. Arregui,et al.  Adenoviral Astrocyte-Specific Expression of BDNF in the Striata of Mice Transgenic for Huntington’s Disease Delays the Onset of the Motor Phenotype , 2011, Cellular and Molecular Neurobiology.

[42]  J. Rossignol,et al.  Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: Morphological and behavioral outcomes , 2011, Behavioural Brain Research.

[43]  Reid L Skeel,et al.  Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease , 2010, Behavioural Brain Research.

[44]  M. Hayden,et al.  BDNF Overexpression in the Forebrain Rescues Huntington's Disease Phenotypes in YAC128 Mice , 2010, The Journal of Neuroscience.

[45]  J. McGinty,et al.  An intrastriatal brain-derived neurotrophic factor infusion restores striatal gene expression in Bdnf heterozygous mice , 2010, Brain Structure and Function.

[46]  N. Urbán,et al.  BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease , 2010, Gene Therapy.

[47]  J. Nolta,et al.  Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. , 2010, Advanced drug delivery reviews.

[48]  M. Matin,et al.  Systemic transplantation of mesenchymal stem cells can reduce cognitive and motor deficits in rats with unilateral lesions of the neostriatum , 2010, Neurological research.

[49]  D. Prockop,et al.  Human Multipotent Stromal Cells (MSCs) Increase Neurogenesis and Decrease Atrophy of the Striatum in a Transgenic Mouse Model for Huntington's Disease , 2010, PloS one.

[50]  S. Totey,et al.  Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. , 2010, Translational research : the journal of laboratory and clinical medicine.

[51]  Shihua Li,et al.  Huntingtin-associated Protein-1 Interacts with Pro-brain-derived Neurotrophic Factor and Mediates Its Transport and Release* , 2009, The Journal of Biological Chemistry.

[52]  A. Bachoud-Lévi.  Neural grafts in Huntington's disease: viability after 10 years , 2009, The Lancet Neurology.

[53]  Ding-I Yang,et al.  Protective effects of brain-derived neurotrophic factor against neurotoxicity of 3-nitropropionic acid in rat cortical neurons. , 2009, Neurotoxicology.

[54]  A. Hannan,et al.  Wheel running and environmental enrichment differentially modify exon‐specific BDNF expression in the hippocampus of wild‐type and pre‐motor symptomatic male and female Huntington's disease mice , 2009, Hippocampus.

[55]  Danielle A. Simmons,et al.  Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice , 2009, Proceedings of the National Academy of Sciences.

[56]  Eduardo D. Martín,et al.  Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: Involvement of phospholipaseCγ activity and glutamate receptor expression , 2009, Neuroscience.

[57]  L. Goldstein,et al.  Enhanced Sensitivity of Striatal Neurons to Axonal Transport Defects Induced by Mutant Huntingtin , 2008, The Journal of Neuroscience.

[58]  Danielle A. Simmons,et al.  Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: Restoration by the neuroprotective compound CEP-1347 , 2008, Molecular and Cellular Neuroscience.

[59]  E. Tsiridis,et al.  Suppression of bone morphogenetic protein inhibitors promotes osteogenic differentiation: therapeutic implications , 2008, Arthritis research & therapy.

[60]  D. Link,et al.  Hypoxic Preconditioning Results in Increased Motility and Improved Therapeutic Potential of Human Mesenchymal Stem Cells , 2008, Stem cells.

[61]  T. Ben-Hur,et al.  Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. , 2008, Archives of neurology.

[62]  Susumu Tonegawa,et al.  Brain‐derived neurotrophic factor over‐expression in the forebrain ameliorates Huntington’s disease phenotypes in mice , 2008, Journal of neurochemistry.

[63]  A. Kells,et al.  AAV–BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment , 2008, Gene Therapy.

[64]  A. Giralt,et al.  Disruption of striatal glutamatergic transmission induced by mutant huntingtin involves remodeling of both postsynaptic density and NMDA receptor signaling , 2008, Neurobiology of Disease.

[65]  Benjamin M. Wu,et al.  Noggin Suppression Enhances in Vitro Osteogenesis and Accelerates in Vivo Bone Formation* , 2007, Journal of Biological Chemistry.

[66]  M. MacDonald,et al.  Widespread Disruption of Repressor Element-1 Silencing Transcription Factor/Neuron-Restrictive Silencer Factor Occupancy at Its Target Genes in Huntington's Disease , 2007, The Journal of Neuroscience.

[67]  S. Calza,et al.  Low brain‐derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[68]  Danielle A. Simmons,et al.  Brain-Derived Neurotrophic Factor Restores Synaptic Plasticity in a Knock-In Mouse Model of Huntington's Disease , 2007, The Journal of Neuroscience.

[69]  Aman A. Savani,et al.  Practice Advisory: Utility of surgical decompression for treatment of diabetic neuropathy: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology , 2007, Neurology.

[70]  S. Dunnett,et al.  Stem cell transplantation for Huntington's disease , 2007, Experimental Neurology.

[71]  P. Remy,et al.  Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study , 2006, The Lancet Neurology.

[72]  A. Asawachaicharn,et al.  Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis , 2006, Experimental Neurology.

[73]  Elena Cattaneo,et al.  Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. , 2005, Pharmacological research.

[74]  G. Mengod,et al.  Brain-Derived Neurotrophic Factor Regulates the Onset and Severity of Motor Dysfunction Associated with Enkephalinergic Neuronal Degeneration in Huntington's Disease , 2004, The Journal of Neuroscience.

[75]  M. Migita,et al.  Adipogenic differentiation by adipose-derived stem cells harvested from GFP transgenic mice-including relationship of sex differences. , 2004, Biochemical and biophysical research communications.

[76]  L. Lescaudron,et al.  AUTOLOGOUS ADULT BONE MARROW STEM CELL TRANSPLANTATION IN AN ANIMAL MODEL OF HUNTINGTON'S DISEASE: BEHAVIORAL AND MORPHOLOGICAL OUTCOMES , 2003, The International journal of neuroscience.

[77]  D. Craufurd,et al.  Behavioral changes in Huntington Disease. , 2001, Neuropsychiatry, neuropsychology, and behavioral neurology.

[78]  K. Marder,et al.  An overview of psychiatric symptoms in Huntington’s disease , 2001, Current psychiatry reports.

[79]  Blair R. Leavitt,et al.  Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.

[80]  Anne-Catherine Bachoud-Lévi,et al.  Motor and cognitive improvements in patients with Huntington's disease after neural transplantation , 2000, The Lancet.

[81]  E. Arenas,et al.  Brain‐Derived Neurotrophic Factor, Neurotrophin‐3, and Neurotrophin‐4/5 Prevent the Death of Striatal Projection Neurons in a Rodent Model of Huntington's Disease , 2000, Journal of neurochemistry.

[82]  P Aebischer,et al.  Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. , 2000, Human gene therapy.

[83]  D. Trono,et al.  A Third-Generation Lentivirus Vector with a Conditional Packaging System , 1998, Journal of Virology.

[84]  A. Björklund,et al.  Protection of the Neostriatum against Excitotoxic Damage by Neurotrophin-Producing, Genetically Modified Neural Stem Cells , 1996, The Journal of Neuroscience.

[85]  S. Folstein,et al.  The psychopathology of Huntington's disease , 1995, Biological Psychiatry.

[86]  K. Weinberg,et al.  Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells , 1995, Journal of virology.

[87]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[88]  C. Antoniades,et al.  Huntington's disease and cell therapies: past, present, and future. , 2013, Methods in molecular biology.

[89]  J. Collins,et al.  A fully humanized transgenic mouse model of Huntington disease. , 2013, Human molecular genetics.

[90]  S. Dunnett,et al.  Cell-based treatments for huntington's disease. , 2011, International review of neurobiology.

[91]  Qi Zhang,et al.  A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury. , 2008, Cytotherapy.

[92]  S. Dunnett,et al.  Human stem cells for CNS repair , 2007, Cell and Tissue Research.

[93]  J. Nolta,et al.  Establishment and Transduction of Primary Human Stromal/Mesenchymal Stem Cell Monolayers , 2006 .

[94]  K. Mitrophanous,et al.  Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE) , 2005, Gene Therapy.

[95]  Vincent Frouin,et al.  Striatal neural grafting improves cortical metabolism in Huntington's disease patients. , 2004, Brain : a journal of neurology.

[96]  J. Alberch,et al.  Neurotrophic factors in Huntington's disease. , 2004, Progress in brain research.

[97]  Folstein Se.  The psychopathology of Huntington's disease. , 1991 .

[98]  B. Nilsson,et al.  Cryopreserved Mesenchymal Stromal Cells Display Impaired Immunomodulatory and Therapeutic Properties ? , 2022 .